Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A non-interventional study assessing Quality of life and clinical outcomes in metastatic colorectal cancer patients treated with FOLFIRI and aflibercept in Germany, Switzerland, and Austria (GSA): QoLiTrap-study

Trial Profile

A non-interventional study assessing Quality of life and clinical outcomes in metastatic colorectal cancer patients treated with FOLFIRI and aflibercept in Germany, Switzerland, and Austria (GSA): QoLiTrap-study

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms QoLiTrap
  • Most Recent Events

    • 03 Jul 2021 Results (n=1277) presented at the 23rd World Congress on Gastrointestinal Cancer.
    • 08 Jun 2021 Results assessing impact of RAS status and prior targeted therapy received (n=1277) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 12 Sep 2017 Interim results (data cut-off: 02 March 2017, n=576) presented at the 42nd European Society for Medical Oncology Congress.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top